Literature DB >> 16222912

Treatment of comorbidity in conduct disorder with attention-deficit hyperactivity disorder (ADHD).

Atilla Turgay1.   

Abstract

Conduct disorder (CD) is one of the most common psychiatric disorders in childhood and adolescence. It is characterized by a variety of chronic antisocial behaviors, a repetitive and persistent pattern of behavior that violates the basic rights of others, major age-appropriate societal norms, or both. Aggressive behavior, lying, stealing, fire-setting, and running away from home and school are the most frequent manifestations of CD and are often accompanied by hyperactivity, impulsive behavior, explosiveness, cognitive and learning problems, and poor social skills. The rate of comorbidity is high, with attention-deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) being the most common; comorbid anxiety and depressive disorders are also seen, especially in adolescents. The diagnostic process should include the use of structured interviews, and scores from reliable and valid rating scales that cover all psychiatric disorders must be considered in the differential diagnosis, because CD alone is an extreme rarity and multiple disorders are almost always the rule rather than exception. Treatment should include parenting skills training combined with training of the child to improve his or her relationships with peers, academic performance, and compliance with legitimate demands of authority figures. The appropriate use of medications and integration of patient/parent education and support, as well as individual, group, family, residential, and inpatient treatment may be beneficial for patients with CD and ADHD. The article describes a number of psychopharmacological agents that are used in patients with CD with ADHD and other comorbid disorders. Drugs that may be useful include psychostimulants; atomoxetine (Strattera); antidepressants (imipramine [Tofranil], desipramine [Norpramin]); Selective Serotonin Reuptake Inhibitors (SSRIs); atypical antipsychotics such as risperidone (Risperdal); or mood regulators including lithium (Eskalith).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16222912

Source DB:  PubMed          Journal:  Essent Psychopharmacol        ISSN: 1087-495X


  6 in total

1.  A multidimensional approach to medication selection in the treatment of children and adolescents with ADHD.

Authors:  Atilla Turgay
Journal:  Psychiatry (Edgmont)       Date:  2007-08

2.  Behavioral symptoms and psychiatric disorders in child and adolescent long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.

Authors:  Wei Liu; Yin Ting Cheung; Tara M Brinkman; Pia Banerjee; Deokumar Srivastava; Vikki G Nolan; Hongmei Zhang; James G Gurney; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Kevin R Krull
Journal:  Psychooncology       Date:  2018-03-30       Impact factor: 3.894

3.  Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.

Authors:  Peter M Wehmeier; Alexander Schacht; Ralf W Dittmann; Karin Helsberg; Christian Schneider-Fresenius; Martin Lehmann; Monika Bullinger; Ulrike Ravens-Sieberer
Journal:  Qual Life Res       Date:  2010-12-07       Impact factor: 4.147

4.  Major Depression with ADHD: In Children and Adolescents.

Authors:  Atilla Turgay; Rubaba Ansari
Journal:  Psychiatry (Edgmont)       Date:  2006-04

5.  High Correspondence Between Child Behavior Checklist Rule Breaking Behavior Scale with Conduct Disorder in Males and Females.

Authors:  Amy M Yule; Maura DiSalvo; Timothy E Wilens; Janet Wozniak; Stephen V Faraone; Rachael M Lyons; K Yvonne Woodworth; Joseph Biederman
Journal:  Child Psychiatry Hum Dev       Date:  2020-12

Review 6.  The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.

Authors:  Mark R Libowitz; Erika L Nurmi
Journal:  Front Psychiatry       Date:  2021-03-12       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.